LOGIN  |  REGISTER
Amneal Pharmaceuticals
C4 Therapeutics

Dexcom Publishes Annual Sustainability Report

April 03, 2024 | Last Trade: US$70.48 1.32 -1.84
  • Report advances Dexcom’s corporate sustainability disclosures, including expanded greenhouse gas emissions data and greater transparency in pay-equity practices

SAN DIEGO / Apr 03, 2024 / Business Wire / DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its annual Sustainability Report. This report provides updates on key corporate sustainability initiatives that are aligned with Dexcom’s core values and business strategy.

“We are always working to advance the interests of our stakeholders, including our global customer base, employees and their families, caregivers, our communities, and our shareholders,” said Kevin Sayer, chairman, president and CEO of Dexcom. “We see an inherent connection between sustainability and strategy and look forward to continuing to drive advances in global health through access to Dexcom CGM technology.”

Dexcom’s sustainability initiatives are integrated as foundational elements of the company’s core values and business strategy. The sustainability report is once again framed according to the company’s four core values: Listen, Think Big, Be Dependable, and Serve with Integrity.

Highlights from this year’s report include:

  • Updates related to the company’s multifaceted access to healthcare strategy, which resulted in the largest expansion of reimbursed coverage in Dexcom’s history.
  • Enhanced human capital reporting, including the results of an externally conducted adjusted pay gap analysis, which demonstrated the company’s commitment to pay equity.
  • A demonstration of the company’s commitment to setting science-based, near-term emissions targets by joining the Science Based Targets initiative (SBTi), along with expanded greenhouse gas emissions reporting.

Dexcom’s annual Sustainability Report can be found on the company’s investor relations site at investors.dexcom.com. All data in the report reflects fiscal year 2023, unless noted otherwise.

About DexCom, Inc.

DexCom, Inc. empowers people to take control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB